| . | n . | Gender Female: n (%) Male: n (%) . | Age (years) Mean ± SD . | TSH (IU/mL) Mean ± SD . | Benign n (%) . | DTC n (%) . |
|---|---|---|---|---|---|---|
| Non-AITD | 1731 | 1300 (75.1%) 431 (24.9%) | 49.8 ± 16.0 | 1.48 ± 0.81 | 1205 (69.6%) | 576 (30.4%) |
| AITD | 329 | 280 (85.1%) 49 (14.9%) | 45.6 ± 15.9 | 2.09 ± 0.98 | 176 (53.5%) | 153 (46.5%) |
| OR (95% CI) P value | n/a | 1.89 (1.37-2.62) 0.0001 | P < 0.0001 | P < 0.0001 | 0.55 (0.43-0.70) < 0.0001 | |
| TPO+ | 103 | 52/2 | 42.5 ± 14.6 | 2.44 ± 0.99 | 30 (55.6%) | 24 (44.4%) |
| TPO− | 54 | 88/15 | 45.1 ± 15.3 | 1.87 ± 0.91 | 48 (46.6%) | 55 (53.4%) |
| OR (95% CI) P value | n/a | 4.43 (0.97-20.16) 0.056 | P = 0.29 | P = 0.0007 | 0.70 (0.36-1.35) 0.32 |
| . | n . | Gender Female: n (%) Male: n (%) . | Age (years) Mean ± SD . | TSH (IU/mL) Mean ± SD . | Benign n (%) . | DTC n (%) . |
|---|---|---|---|---|---|---|
| Non-AITD | 1731 | 1300 (75.1%) 431 (24.9%) | 49.8 ± 16.0 | 1.48 ± 0.81 | 1205 (69.6%) | 576 (30.4%) |
| AITD | 329 | 280 (85.1%) 49 (14.9%) | 45.6 ± 15.9 | 2.09 ± 0.98 | 176 (53.5%) | 153 (46.5%) |
| OR (95% CI) P value | n/a | 1.89 (1.37-2.62) 0.0001 | P < 0.0001 | P < 0.0001 | 0.55 (0.43-0.70) < 0.0001 | |
| TPO+ | 103 | 52/2 | 42.5 ± 14.6 | 2.44 ± 0.99 | 30 (55.6%) | 24 (44.4%) |
| TPO− | 54 | 88/15 | 45.1 ± 15.3 | 1.87 ± 0.91 | 48 (46.6%) | 55 (53.4%) |
| OR (95% CI) P value | n/a | 4.43 (0.97-20.16) 0.056 | P = 0.29 | P = 0.0007 | 0.70 (0.36-1.35) 0.32 |
Abbreviations: AITD, autoimmune thyroid disease (see text); DTC, differentiated thyroid cancer; OR, odds ratio; TPO+, thyroid peroxidase antibodies titers > 100 IU/ml; TPO−, thyroid peroxidase antibodies titers < 100 IU/ml; SD, standard deviation.
| . | n . | Gender Female: n (%) Male: n (%) . | Age (years) Mean ± SD . | TSH (IU/mL) Mean ± SD . | Benign n (%) . | DTC n (%) . |
|---|---|---|---|---|---|---|
| Non-AITD | 1731 | 1300 (75.1%) 431 (24.9%) | 49.8 ± 16.0 | 1.48 ± 0.81 | 1205 (69.6%) | 576 (30.4%) |
| AITD | 329 | 280 (85.1%) 49 (14.9%) | 45.6 ± 15.9 | 2.09 ± 0.98 | 176 (53.5%) | 153 (46.5%) |
| OR (95% CI) P value | n/a | 1.89 (1.37-2.62) 0.0001 | P < 0.0001 | P < 0.0001 | 0.55 (0.43-0.70) < 0.0001 | |
| TPO+ | 103 | 52/2 | 42.5 ± 14.6 | 2.44 ± 0.99 | 30 (55.6%) | 24 (44.4%) |
| TPO− | 54 | 88/15 | 45.1 ± 15.3 | 1.87 ± 0.91 | 48 (46.6%) | 55 (53.4%) |
| OR (95% CI) P value | n/a | 4.43 (0.97-20.16) 0.056 | P = 0.29 | P = 0.0007 | 0.70 (0.36-1.35) 0.32 |
| . | n . | Gender Female: n (%) Male: n (%) . | Age (years) Mean ± SD . | TSH (IU/mL) Mean ± SD . | Benign n (%) . | DTC n (%) . |
|---|---|---|---|---|---|---|
| Non-AITD | 1731 | 1300 (75.1%) 431 (24.9%) | 49.8 ± 16.0 | 1.48 ± 0.81 | 1205 (69.6%) | 576 (30.4%) |
| AITD | 329 | 280 (85.1%) 49 (14.9%) | 45.6 ± 15.9 | 2.09 ± 0.98 | 176 (53.5%) | 153 (46.5%) |
| OR (95% CI) P value | n/a | 1.89 (1.37-2.62) 0.0001 | P < 0.0001 | P < 0.0001 | 0.55 (0.43-0.70) < 0.0001 | |
| TPO+ | 103 | 52/2 | 42.5 ± 14.6 | 2.44 ± 0.99 | 30 (55.6%) | 24 (44.4%) |
| TPO− | 54 | 88/15 | 45.1 ± 15.3 | 1.87 ± 0.91 | 48 (46.6%) | 55 (53.4%) |
| OR (95% CI) P value | n/a | 4.43 (0.97-20.16) 0.056 | P = 0.29 | P = 0.0007 | 0.70 (0.36-1.35) 0.32 |
Abbreviations: AITD, autoimmune thyroid disease (see text); DTC, differentiated thyroid cancer; OR, odds ratio; TPO+, thyroid peroxidase antibodies titers > 100 IU/ml; TPO−, thyroid peroxidase antibodies titers < 100 IU/ml; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
